Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 17:10:597422.
doi: 10.3389/fonc.2020.597422. eCollection 2020.

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis

Ke-Hao Pan  1   2 , Jin-Feng Wang  3 , Chun-Ying Wang  4 , Abdul Aziz Nikzad  1   2 , Fang Q Kong  5 , Li Jian  6 , Yin-Qiu Zhang  7 , Xiao-Ming Lu  3 , Bin Xu  1 , Ya-Li Wang  1 , Ming Chen  1
Affiliations

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis

Ke-Hao Pan et al. Front Oncol. .

Abstract

Background: To systematically review the clinical value of 18F-DCFPyL prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in the diagnosis of prostate cancer (PCa).

Methods: Literature concerning 18F-DCFPyL PSMA PET/CT in the diagnosis of prostate cancer published from 2015 to 2020 was electronically searched in the databases including PubMed and Embase. Statistical analysis was carried out with STATA 15 software, and the quality of included studies was tested with quality assessment of diagnostic accuracy studies (QUADAS) items. The heterogeneity of the included data was tested.

Results: In total, nine pieces of literature involving 426 patients met the inclusion criteria. The heterogeneity of the study group was not obvious. The SEN, SPE, LR+, LR-, DOR as well as AUC of 18F-DCFPyL PSMA PET/CT diagnosis of prostate cancer were 0.91, 0.90, 8.9, 0.10, 93, and 0.93. The pooled DR of 18F-DCFPyL labeled PSMA PET/CT in PCa was 92%. The pooled DR was 89% for PSA≥0.5 ng/ml and 49% for PSA < 0.5ng/ml.

Conclusion: 18F-DCFPyL PSMA PET/CT had good sensitivity and specificity for the diagnosis of prostate cancer. The DR of 18F-DCFPyL PSMA PET/CT was correlated with PSA value. Further large-sample, high-quality studies were needed.

Keywords: 18F-DCFPyL PSMA PET/CT; diagnosis; imaging; meta-analysis; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow Chart.
Figure 2
Figure 2
Quality evaluation of the inccluded studies.
Figure 3
Figure 3
The combined statistics.
Figure 4
Figure 4
SROC curves of 18F-DCFPyL PSMA PET/CT.
Figure 5
Figure 5
Forest map of 18F-DCFPyL PSMA PET/CT.
Figure 6
Figure 6
Sensitivity analysis of studies. Goodness of fit refers to the fitting degree of the regression line to the observed value. The statistic to measure goodness of fit is R2. The maximum value of R2 is 1. The closer the value of R2 is to 1, the better the fitting degree of the regression line to the observed value is; on the contrary, the smaller the value of R2 is, the worse the fitting degree of the regression line to the observed value is.
Figure 7
Figure 7
The Fagan map.
Figure 8
Figure 8
Deeks’ test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev (2014) 15(22):9575–8. - PubMed
    1. Kopka K, Benesova M, Barinka C, et al. . Glu-ureido-based inhibtros of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers. J Nucl Med (2017) 58(Suppl 2):17S–26S. - PubMed
    1. Giorgio T, Salvatore A, Pizzuto DA, Giovanella L, Prior JO, Ceriani L. Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. Cancers (2019) 11:710. 10.3390/cancers11050710 - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin (2018) 68(1):7–30. - PubMed
    1. Tao Z-Q, ShiI A-M, Wang K-X, Zhang W-D. Epidemiology of prostate cancer: Current status. Eur Rev Med Pharmacol Sci (2015) 19(5):805–12. - PubMed

Publication types